Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Braz. J. Pharm. Sci. (Online) ; 58: e20607, 2022. tab, graf
Article in English | LILACS | ID: biblio-1420427

ABSTRACT

Abstract The main aim of the paper is to assess whether vitamin C, vitamin D, and natural honey can be administered in the course of the COVID-19 pandemic for promising in line methods with recent evidence. Both systematic literature and clinical trial identification were conducted by searching various databases. A total 58 articles and 29 clinical trials were selected wherein 11 for vitamin C, 16 for vitamin D, and 2 for natural honey were identified for analysis. The high doses of vitamin C (i.e. '200 mg/kg body weight/day, divided into 4 doses') has been found to reduce COVID-19 lung damage, various flu infections. Additionally, the high doses of vitamin C can shorten around 7.8% stay in the intensive care unit. At the same time, vitamin D can effectively protect from lung injury and acute respiratory infections whereas vitamin D deficiency severely affects 75% of the institutionalized people (serum 25(OH) D < 25 nmol/L). Meanwhile, natural honey which contains proteins (0.1-0.4%); ash (0.2%); water (15-17%) has potential antiviral effects and the ability to improve immunity. Therefore, the administration of vitamins and honey is the promising evidence-based approach for reducing fatalities, saving lives, and bringing the COVID-19 pandemic to a rapid end. It is believed that the utilization of vitamin C, vitamin D, and natural honey with the current treatment may be effective in treating COVID-19-caused fatal complications such as pneumonia. Therefore, high-level clinical studies are required on COVID-19 to administrate the effects of vitamins and natural honey


Subject(s)
Vitamins/adverse effects , COVID-19 Drug Treatment/classification , Honey/adverse effects , Antiviral Agents/administration & dosage , Pneumonia/complications , Ascorbic Acid/adverse effects , Vitamin D/adverse effects , COVID-19/prevention & control
3.
Rev. Assoc. Med. Bras. (1992) ; 64(7): 643-648, July 2018. tab, graf
Article in English | LILACS | ID: biblio-976834

ABSTRACT

SUMMARY Objective: The objective of this study was to analyse the existing bibliographic production on clinical trials related to the use of vitamin D for oral treatment of psoriasis. Method: A literature review of clinical trials related to the use of vitamin D for oral treatment of psoriasis, published in the LILACS, Scielo, Medline, PubMed and Cochrane Library from 1986 to 2013. The search included the following terms: "Psoriasis and oral Vitamin D"; "psoríase e vitamina D oral". Results: After analysing the titles and summaries, 10 articles met the eligibility criteria. Discussion: According to the literature, most tests were made in moderate psoriasis with doses ranging from 0.25 to 2μg, demonstrating improvement with this treatment modality. Some studies suggest the use of high doses, but the biggest concern is hypercalciuria as a side effect. Conclusion: The use of active metabolites of vitamin D orally for the treatment of psoriasis showed efficacy and safety.


RESUMO OBJETIVO: O objetivo deste estudo foi analisar a produção bibliográfica existente sobre os ensaios clínicos relacionados ao uso da vitamina D para tratamento por via oral da psoríase. MÉTODOS: Revisão de literatura de ensaios clínicos relacionados ao uso de vitamina D para tratamento por via oral da psoríase publicados no Lilacs, SciELO, MedLine, PubMed e Biblioteca Cochrane no período de 1986 a 2013. A pesquisa incluiu os seguintes termos: "Psoriasis and oral Vitamin D"; "psoríase e vitamina D oral". RESULTADOS: Depois de analisar os títulos e resumos, dez artigos preencheram os critérios de elegibilidade. DISCUSSÃO: Segundo a literatura, a maioria dos ensaios foi realizada na psoríase moderada, com dose que varia de 0,25 a 2 μg, demonstrando melhora com esta modalidade terapêutica. Alguns estudos sugerem o uso de doses elevadas, porém a maior preocupação é a hipercalciúria como efeito colateral. CONCLUSÃO: O uso de metabólitos ativos de vitamina D por via oral para o tratamento da psoríase demonstrou eficácia e segurança com relação aos efeitos colaterais.


Subject(s)
Humans , Female , Psoriasis/drug therapy , Vitamin D/therapeutic use , Vitamins/therapeutic use , Psoriasis/etiology , Vitamin D/adverse effects , Vitamin D Deficiency/complications , Vitamins/adverse effects , Administration, Oral , Clinical Trials as Topic
4.
J. bras. nefrol ; 39(4): 467-469, Oct.-Dec. 2017.
Article in English | LILACS | ID: biblio-893796

ABSTRACT

Abstract A previously healthy 24 yo male presented with a two-month history of epigastric pain, nausea, vomiting, fatigue and malaise. He reported abuse of different substances, including an injectable veterinary vitamin compound, which contains high doses of vitamin A, D and E, and an oily vehicle that induces local edema and enhances muscle volume. Serum creatinine was 3.1 mg/dL, alanine transaminase 160 mg/dL, aspartate transaminase 11 mg/dL, total testosterone 23 ng/dL, 25-OH-vitamin D >150 ng/mL (toxicity >100), 1,25-OH-vitamin D 80 pg/mL, vitamin A 0.7 mg/dL, parathormone <3 pg/mL, total calcium 13.6 mg/dL, 24-hour urinary calcium 635 mg/24h (RV 42-353). A urinary tract ultrasound demonstrated signs of parenchymal nephropathy. The diagnosis was hypercalcemia and acute renal failure secondary to vitamin D intoxication. He was initially treated with intravenous hydration, furosemide and prednisone. On the fifth day of hospitalization a dose of pamidronate disodium was added. The patient evolved with serum calcium and renal function normalization. Thirty days later he presented normal clinical and laboratory tests, except 25-OH-vitamin D that was persistently increased (107 ng/mL), as it may take several months to normalize. This case report is a warning of the risks related to the use of veterinary substances for aesthetics purposes.


Resumo Um paciente de 24 anos do sexo masculino, previamente hígido, apresentou-se com uma história de dois meses de dor epigástrica, náuseas, vômitos, fadiga e mal-estar. Ele relatava abuso de diferentes substâncias, incluindo um composto vitamínico veterinário injetável contendo altas doses de vitamina A, D e E, e um veículo oleoso que induz edema local com aumento de volume muscular. A creatinina sérica estava 3,1 mg/dL, alanina transaminase 160 mg/dL, aspartato transaminase 11 mg/dL, testosterona total 23 ng/dL, 25-OH-vitamina D > 150 ng/mL (toxicidade > 100), 1,25-OH-vitamina D 80 pg/mL, vitamina A 0,7 mg/dL, paratormônio < 3 pg/mL, cálcio total 13,6 mg/dL, cálcio urinário de 24h 635 mg/24h (VR 42-353). Uma ultrassonografia do trato urinário demonstrou sinais de nefropatia parenquimatosa. O diagnóstico foi hipercalcemia e insuficiência renal aguda secundária a intoxicação por vitamina D. Ele foi tratado inicialmente com hidratação intravenosa, furosemida e prednisona. No quinto dia de hospitalização uma dose de pamidronato dissódico foi adicionada. O paciente evoluiu com normalização do cálcio sérico e da função renal. Trinta dias depois ele apresentou testes clínicos e laboratoriais normais, exceto a 25-OH-vitamina D que estava persistentemente elevada (107 ng/mL), já que ela pode demorar vários meses para normalizar. Este relato de caso é um alerta aos riscos relacionados ao uso de substâncias veterinárias para fins estéticos.


Subject(s)
Humans , Male , Young Adult , Vitamin A/adverse effects , Vitamin D/adverse effects , Vitamin E/adverse effects , Veterinary Drugs/adverse effects , Acute Kidney Injury/chemically induced , Hypercalcemia/chemically induced , Vitamins/adverse effects , Acute Kidney Injury/complications , Hypercalcemia/complications
5.
J. bras. nefrol ; 36(2): 132-138, Apr-Jun/2014. tab, graf
Article in Portuguese | LILACS | ID: lil-714666

ABSTRACT

Introdução: Há poucos dados na literatura sobre a suplementação de vitamina D e cálcio e o desenvolvimento de cálculos renais. Objetivo: Avaliar o efeito de doses elevadas de vitamina D3 (V), com suplemento de cálcio (Ca) no desenvolvimento de litíase em modelo experimental. Métodos: Pastilhas foram inseridas na bexiga de ratos, que receberam V com ou sem Ca. Ratos foram divididos em seis grupos: 1. Sham; 2. Controle com pastilha, 3. Controle com V, 4. Pastilha + V, 5. Pastilha + Ca e 6. Pastilha + Ca + V. Resultados: Observou-se 50% e 17% de redução na formação de cálculos, respectivamente nos grupos 5 e 6 em comparação ao grupo 2 (p < 0,005). Não foram observadas hipercalcemia ou hipercalciúria em todos os grupos. Encontramos no grupo 6 (p = 0,03) uma redução significativa na calciúria. Conclusão: A administração de V associada com Ca diminuiu significantemente a formação de cálculos e reduziu significantemente a calciúria, sugerindo uma interferência benéfica na fisiopatologia litogênica. .


Introduction: There is little information in the literature relating supplementary oral usage of vitamin D and calcium to the development of kidney stones. Objective: To evaluate the effect of high dose, 200 IU of vitamin D3 (V) with calcium supplementation (Ca). Methods: Experimental model consists of insertion of pellets into the bladder of rats. V was administered for 30 days with or without Ca. The rats were divided in 6 groups: 1. Sham, 2. Pellets control; 3. V control; 4. Pellets + V; 5. Pellets + Ca and 6. Pellets + Ca + V. Results: 50% and 17% decreases bladder stones formation in groups 5 and 6, p < 0.005 comparing with the group 2 were observed. There was no hypercalcemia or hypercalciuria in all groups. We observed a significant decrease in calciuria in group 6 (p = 0.03). Conclusion: The administration of the V associated with Ca significantly decreased the formation of stones and caused a significant reduction in urinary calcium, suggesting a protection in the lithogenic pathophysiology. .


Subject(s)
Animals , Rats , Calcium/administration & dosage , Cholecalciferol/adverse effects , Nephrolithiasis/chemically induced , Vitamins/adverse effects , Cholecalciferol/administration & dosage , Dietary Supplements , Disease Models, Animal , Drug Overdose , Rats, Wistar , Vitamins/administration & dosage
6.
Arq. bras. cardiol ; 101(3): 233-239, set. 2013. ilus, tab
Article in Portuguese | LILACS | ID: lil-686545

ABSTRACT

FUNDAMENTO: Estudos de intervenção mostraram aumento da mortalidade em pacientes que receberam betacaroteno. Contudo, não são conhecidos os mecanismos envolvidos nesse fenômeno. OBJETIVO: Avaliar a influência do betacaroteno sobre o estresse oxidativo e a expressão de conexina 43 em coração de ratos. MÉTODOS: Ratos Wistar, pesando aproximadamente 100 g, foram alocados em dois grupos: Grupo Controle (n = 30), que recebeu a dieta usada de rotina em nosso laboratório, e Grupo Betacaroteno (n = 28), que recebeu betacaroteno (na forma de cristal, adicionado e misturado à dieta) na dose de 500 mg de betacaroteno/kg de dieta. Os animais receberam tratamento até que atingissem entre 200 e 250 g, quando eram sacrificados. Foram coletados sangue, fígado e coração para realização de Western blotting e imunoistoquímica para conexina 43; foram realizados estudos morfométricos, dosagens de betacaroteno por cromatografia líquida de alta eficiência bem como de glutationa reduzida, glutationa oxidada e hidroperóxidos de lipídeos por análises bioquímicas. RESULTADOS: O betacaroteno foi detectado apenas no fígado dos animais do Grupo Betacaroteno (288 ± 94,7 µg/kg). Os níveis de glutationa reduzida/glutationa oxidada foram maiores no fígado e no coração dos animais do Grupo Betacaroteno (fígado - Grupo Controle: 42,60 ± 1,62; fígado - Grupo Betacaroteno: 57,40 ± 5,90; p = 0,04; coração: - Grupo Controle: 117,40 ± 1,01; coração - Grupo Betacaroteno: 121,81 ± 1,32 nmol/mg proteína; p = 0,03). O conteúdo de conexina 43 total foi maior no Grupo Betacaroteno. CONCLUSÃO: O betacaroteno apresentou efeito benéfico, caracterizado pelo aumento da comunicação intercelular e melhora do sistema de defesa antioxidante. Nesse modelo, os mecanismos não explicam a maior mortalidade observada com a suplementação de betacaroteno em estudos clínicos. (Arq Bras Cardiol. 2013; [online].ahead print, PP.0-0).


BACKGROUND: Intervention studies have shown an increased mortality in patients who received beta-carotene. However, the mechanisms involved in this phenomenon are still unknown. OBJECTIVE: Evaluate the influence of beta-carotene on oxidative stress and the expression of connexin 43 in rat hearts. METHODS: Wistar rats, weighing approximately 100 g, were allocated in two groups: Control Group (n=30), that received the diet routinely used in our laboratory, and Beta-Carotene Group (n = 28), which received beta-carotene (in crystal form, added and mixed to the diet) at a dose of 500 mg of beta-carotene/kg of diet. The animals received the treatment until they reached 200-250g, when they were sacrificed. Samples of blood, liver and heart were collected to perform Western blotting and immunohistochemistry for connexin 43; morphometric studies, dosages of beta-carotene by high-performance liquid chromatography as well as reduced glutathione, oxidized glutathione and lipids hydroperoxides were performed by biochemical analysis. RESULTS: Beta-carotene was detected only in the liver of Beta-Carotene Group animals (288 ± 94.7 µg/kg). Levels of reduced/oxidized glutathione were higher in the liver and heart of Beta-Carotene Group animals (liver - Control Group: 42.60 ± 1.62; liver - Beta-Carotene Group: 57.40 ± 5.90; p = 0.04; heart: - Control Group: 117.40 ± 1.01; heart - Beta-Carotene Group: 121.81 ± 1.32 nmol/mg protein; p = 0.03). The content of total connexin 43 was larger in Beta-Carotene Group. CONCLUSION: Beta-carotene demonstrated a positive effect, characterized by the increase of intercellular communication and improvement of anti-oxidizing defense system. In this model, mechanism does not explain the increased mortality rate observed with the beta-carotene supplementation in clinical studies. (Arq Bras Cardiol. 2013; [online].ahead print, PP.0-0).


Subject(s)
Animals , Male , Rats , /drug effects , Oxidative Stress/drug effects , Vitamins/pharmacology , beta Carotene/pharmacology , Blotting, Western , /metabolism , Glutathione Disulfide/analysis , Heart Ventricles/chemistry , Immunohistochemistry , Lipid Peroxides/analysis , Liver/chemistry , Rats, Wistar , Ventricular Remodeling , Vitamins/adverse effects , Vitamins/analysis , beta Carotene/adverse effects , beta Carotene/analysis
7.
J. bras. nefrol ; 33(4): 467-471, out.-nov.-dez. 2011. tab
Article in English | LILACS | ID: lil-609061

ABSTRACT

Um rapaz de 19 anos, previamente hígido, procurou o hospital com queixas de anorexia, náuseas e vômitos. Exames laboratoriais revelaram hipercalcemia (valor máximo do cálcio de 14,8 mg/dL) e lesão renal aguda (valor máximo da creatinina de 2,88 mg/dL). O paciente admitiu utilizar uma formulação parenteral de vitaminas A, D e E de uso exclusivo veterinário, contendo 20.000.000 UI de vitamina A; 5.000.000 UI de vitamina D3 e 6.800 UI de vitamina E, por ampola de 100 mL. Ele refere ter usado cerca de 300 mL do produto no último ano. O jovem não estava interessado na quantidade maciça de vitaminas contida no produto, mas apenas no efeito local do veículo oleoso; o edema provocado pela injeção simulava um aumento de massa muscular. O produto, no entanto, foi absorvido e causou hipervitaminose. O nível sérico de 25(OH) vitamina D estava claramente elevado em 150 ng/mL (referência de 30 a 60 ng/mL), mas não tanto quanto em outros casos publicados de intoxicação por vitamina D. A maioria dos casos de hipercalcemia por hipervitaminose D se associa a níveis de 25 (OH)D bem maiores do que 200 ng/mL. O PTH estava indetectável, e outras causas de hipercalcemia foram excluídas. Deste modo, conclui-se que a gravidade da hipercalcemia encontrada neste caso foi resultado do efeito sinérgico da intoxicação pelas vitaminas A e D. O paciente foi tratado com soro fisiológico, furosemida e ácido zolendrônico e evoluiu com normalização rápida dos níveis séricos de cálcio e da função renal.


A previously healthy 19 year-old male presented to the hospital with anorexia, nausea, and vomiting. Laboratory studies were significant for hypercalcemia (peak calcium value of 14.8 mg/dL) and acute kidney injury (peak serum creatinine of 2.88 mg/dL). He admitted to using a parenteral formulation of vitamins A, D and E restricted for veterinary use containing 20,000,000 IU of vitamin A; 5,000,000 IU of vitamin D3; and 6,800 IU of vitamin E per 100 mL vial. The patient stated to have used close to 300 mL of the product over the preceding year. Interestingly, the young man was not interested in the massive amounts of vitamins that the product contained; he was only after the local effects of the oily vehicle. The swelling produced by the injection resulted in a silicone-like effect, which gave the impression of bigger muscles. Nevertheless, the product was absorbed and caused hypervitaminosis. The serum level of 25(OH) vitamin D was clearly elevated at 150 ng/mL (reference range from 30 to 60 ng/mL), but in most published cases of vitamin D toxicity, serum levels have been well above 200 ng/mL. His PTH level was undetectable and other potential causes of hypercalcemia were excluded. Therefore, we posit that the severity of the hypercalcemia observed in this case was the result of a synergistic effect of vitamins A and D. The patient was treated with normal saline, furosemide and zolendronic acid, with rapid normalization of calcium levels and renal function.


Subject(s)
Humans , Male , Young Adult , Acute Kidney Injury/chemically induced , Hypercalcemia/chemically induced , Parenteral Nutrition Solutions/adverse effects , Substance-Related Disorders/complications , Vitamin A/adverse effects , Vitamin D/adverse effects , Vitamin E/adverse effects , Vitamins/adverse effects , Drug Overdose , Veterinary Drugs
8.
Arch. latinoam. nutr ; 61(3): 247-253, sep. 2011. tab
Article in Spanish | LILACS | ID: lil-698148

ABSTRACT

En el presente trabajo se estudió el efecto de la administración subcutánea de 250, 500 y 750 μg (10.000, 20.000 y 30.000 UI, respectivamente) de vitamina D3 (calciferol)/día durante 8 días, sobre las concentraciones séricas de vitamina D3 y de 25-hidroxivitamina D3 (25-OH-D3) y sobre las concentraciones séricas y tisulares de Ca, Zn, Cu y Fe en 45 ratas macho Wistar, de 12 semanas de edad y con pesos entre 180 y 200 gramos. El grupo control estuvo integrado por 15 ratas Wistar sanas, con género, edad y peso similares a los animales tratados. La administración del calciferol a dosis altas produjo una hipervitaminosis D que se caracterizo por un aumento en el contenido sérico de la vitamina D3 y de 25-OH-D3, diversos signos clínicos (por ejemplo, anorexia, pérdida marcada de peso, diarreas sanguinolentas, conjuntivitis bilateral y muerte), hipercalcemia, hipocincemia, hipercupremia, hipoferremia y una alteración en la distribución tisular de Ca, Zn, Cu y Fe en comparación con los controles no tratados. La hipercalcemia y la inflamación son un hallazgo prominente en la hipervitaminosis D. La inflamación o la infección inducen cambios sistémicos, conocidos colectivamente como la respuesta de fase aguda. Entre las variadas alteraciones que produce esta respuesta encontramos hipoferremia, hipocincemia e hipercupremia. Es probable que estas respuestas estén mediadas, en parte, por la producción y liberación de citocinas como la interleucina 1, interferones (IFN-alfa), la interleucina 6 (Il-6) y el factor de necrosis tumoral (TNF). El desarrollo de la hipoferremia durante la inflamación requiere de hepcidina, un péptido rico en enlaces disulfuro, regulador del metabolismo del hierro, sintetizado en el hígado en respuesta a la liberación de Il-6 durante la inflamación/infección. En conclusión, nuestros resultados proporcionan evidencias que la administración de altas dosis de vitamina D, a corto plazo, determina diversos signos clínicos, produce un marcado aumento de las concentraciones séricas de la vitamina D3 y de 25-OH-D3 y una marcada alteración en las concentraciones séricas y tisulares de Ca, Zn, Cu y Fe, que dependen de las dosis inyectadas de vitamina D.


In the present work the effect of subcutaneous administration of 250, 500 and 750 ìg (10.000, 20.000 and 30.000 IU, respectively) of vitamin D3 (calciferol) daily for eight days, on serum concentrations of vitamin D3 and 25- hydroxyvitamin D3 (25-OH-D3) and on serum and tissue concentrations of Ca, Zn, Cu and Fe in 45 white male Wistar rats, aged 12 weeks and weighing 180-200 g, have been studied. The group control was integrated by 15 healthy rats with similar characteristics (strain, gender, age and weight) that treated animals. Administration of high doses of calciferol produced a hypervitaminosis D characterized by a significant (p3 and 25-OH-D3, diverse clinical signs (such as, anorexia, marked loss of body weight, bloody diarrhea, bilateral conjunctivitis, and death), hypercalcemia, hypozincaemia, hypercupremia, hypoferraemia and an alteration in the tissue distribution of Ca, Zn, Cu and Fe as compared with untreated controls. Hypercalcemia and inflammation are prominent findings in hypervitaminosis D. Inflammation or infection induce systemic changes, collectively known as the acute phase response. Among the varied alterations that together produce this response are hypoferraemia, hypozincaemia and hypercupremia. It is likely that these responses are mediated, in part, by production and release of cytokines such as interleukin 1, interferons (IFN-alpha), interleukin 6 (Il-6) and tumor necrosis factor (TNF). The development of hypoferraemia during inflammation requires hepcidin, an iron regulatory hormone, a disulfide-rich peptide, produced in the liver in response to the release of Il-6 during inflammation/ infection. In conclusion, our results provide evidence that short-term administration of high doses of vitamin D determined diverse clinical signs and produced a marked increase of serum vitamin D3 and 25-OH-D3 and a marked alteration in the serum and tissue concentrations of Ca, Zn, Cu, and Fe. These changes depend on the doses given of vitamin D.


Subject(s)
Animals , Male , Rats , Calcifediol/analogs & derivatives , Cholecalciferol/administration & dosage , Kidney/chemistry , Liver/chemistry , Vitamins/administration & dosage , Calcifediol/blood , Calcium/analysis , Cholecalciferol/adverse effects , Cholecalciferol/pharmacokinetics , Copper/analysis , Hypercalcemia/blood , Hypercalcemia/chemically induced , Injections, Subcutaneous , Iron/analysis , Rats, Wistar , Vitamins/adverse effects , Vitamins/pharmacokinetics , Zinc/analysis
10.
Rev. Assoc. Med. Bras. (1992) ; 55(4): 452-457, 2009. graf, tab
Article in Portuguese | LILACS | ID: lil-525052

ABSTRACT

OBJETIVOS: Avaliar o efeito da suplementação com vitamina A sobre os níveis de retinol no colostro de puérperas atendidas em maternidade pública de Natal-RN, analisando a influência do estado nutricional materno e retinol no colostro na resposta a esta suplementação. MÉTODOS: Foram coletados 5 ml de sangue em jejum para análise do retinol sérico, e duas amostras de leite, antes e 24h após suplementação. O consumo de vitamina A foi obtido pelo questionário de frequência de consumo. O retinol foi analisado por cromatografia líquida de alta eficiência. RESULTADOS: O consumo de vitamina A foi 1492,4 ± 1264 µgRAE/dia e 23 por cento tinha consumo provavelmente inadequado. No início (0h) e após 24h da suplementação, os grupos comparativo e suplementado apresentaram concentrações séricas de retinol de 1,3 ± 0,4 e 1,4 ± 0,4 µmol/L (7 por cento de deficiência) e 3,5 ± 1,7 µmol/L e 3,3 ± 1,8 µmol/L (p>0,05) no colostro 0h, respectivamente. No grupo suplementado o retinol aumentou no colostro 24h, com valores de 3,6 ± 1,9 e 6,8 ± 2,6 µmol/L (p<0,0001), respectivamente. Mulheres com níveis deficientes de retinol no colostro 0h (<2,04 µmol/L) transferiram mais retinol ao colostro 24h do que as com níveis adequados (326,1 por cento e 86,5 por cento de aumento, respectivamente). CONCLUSÃO: A megadose foi eficaz nas primeiras 24h após a suplementação. Os níveis basais de retinol no colostro influenciaram a resposta à suplementação. As parturientes que apresentaram valores baixos de retinol transferiram mais retinol oriundo da megadose ao leite do que as lactantes com níveis suficientes, possivelmente ressaltando a atuação dos mecanismos de transferência de vitamina A propostos na glândula mamária.


OBJECTIVE: The aim was to evaluate the effect of supplementary vitamin A upon the colostrum retinol levels in puerperal women cared for at a public maternity hospital in Natal, RN, Brazil. Analysis was conducted on the influence of the colostrum retinol and the maternal nutritional condition as response to supplementation. METHODS: For analysis of serum retinol 5ml of fasting blood and two samples of milk were collected before and 24 hours after supplementation. A questionnaire was used to define the frequency of previous vitamin A intake. High Efficiency Liquid Chromatography was used to analyze the retinol. RESULTS: Vitamin A intake was 1492.4 ± 1264 µgRAE/day and 23 percent probably had an inadequate intale. At the beginning of supplementation, 0 hour, and at 24 hours, the control and supplemented groups presented serum retinol concentrations of 1.3 ± 0.4 and 1.4 ± 0.4 µmol/L (7 percent deficiency) and 3.5 ± 1.7 µmol/L and 3.3 ± 1.8 µmol/L (p>0.05) at 0 hour colostrum, respectively. Retinol in the 24 hours milk of the supplemented group increased from of 3.6 ± 1.9 and 6.8 ± 2.6 µmol/L (p<0.0001), respectively. Women with deficient levels of retinol in the colostrum at 0 hour(<2.04 mol/L) transferred more retinol to the colostrum at24 hours milk than those with adequate levels (an increase of 326.1 percent and 86.5 percent, respectively). CONCLUSION: The megadose of vitamin A was efficient in the first 24 hours after supplementation. The supplementation response was influenced by the basal levels of retinol in the colostrum. Parturient women with low initial levels of retinol transferred more retinol to the milk, after the megadose, than nursing women with sufficient levels. This possibly confirms the action of the Vitamin A transfer mechanisms proposed by the mammary gland.


Subject(s)
Adult , Female , Humans , Colostrum/chemistry , Dietary Supplements , Vitamin A , Vitamins , Chi-Square Distribution , Cross-Sectional Studies , Hospitals, Maternity , Hospitals, Public , Milk, Human/chemistry , Nutritional Status/drug effects , Postpartum Period/drug effects , Retinol-Binding Proteins, Plasma/analysis , Retinol-Binding Proteins, Plasma/metabolism , Vitamin A/administration & dosage , Vitamin A/adverse effects , Vitamin A/analysis , Vitamins/administration & dosage , Vitamins/adverse effects , Vitamins/analysis
11.
P. R. health sci. j ; 23(2): 119-120, Jun. 2004.
Article in English | LILACS | ID: lil-390792

ABSTRACT

We tested a dietary supplement formulated with a synergistic combination of vitamins, minerals, herbals in a group of 15 patients with uncontrolled diabetes type II. The supplement was given for 30 days. Fasting blood glucose was measured prior to the supplementation and at the end of the 30 days treatment period. Blood glucose was significantly reduced in all patients with no adverse effects. This orthomolecular correction of faulty glucose metabolism with a combination of nontoxic, safe and fairly inexpensive nutraceuticals needs to be further substantiated. Nervertheless the idea of correcting metabolism with micronutrients is a new concept of genetic nutritioneering that seems appealing and cost effective


Subject(s)
Humans , Male , Female , Adult , Diabetes Mellitus, Type 2 , Dietary Supplements , Blood Glucose/metabolism , Micronutrients/administration & dosage , Minerals/administration & dosage , Vitamins/administration & dosage , Phytotherapy/methods , Herbal Medicine/methods , Micronutrients/adverse effects , Minerals/adverse effects , Pilot Projects , Treatment Outcome , Vitamins/adverse effects
12.
Rev. chil. dermatol ; 20(4): 254-259, 2004. tab, graf
Article in Spanish | LILACS | ID: lil-460824

ABSTRACT

Las formulaciones tópicas de vitamina C y E han demostrado su efectividad en la prevención del fotodaño de la piel. El uso oral de vitaminas A, C, D y E presenta resultados controversiales. Se revisa la literatura, con especial énfasis en los efectos adversos del uso oral de vitaminas.


Subject(s)
Humans , Antioxidants/therapeutic use , Skin Aging , Vitamins/therapeutic use , Administration, Oral , Administration, Topical , Skin , Vitamins/adverse effects , Vitamins/pharmacology
14.
Rev. méd. Minas Gerais ; 9(2): 70-1, abr.-jun. 1999.
Article in Portuguese | LILACS | ID: lil-247704

ABSTRACT

Os autores discutem sobre o uso e abuso de vitaminas, salientando as poucas referências sobre os riscos de seu uso inadequado. Comentam sobre alguns fatores que poderiam contribuir para esse emprego abusivo de vitaminas.


Subject(s)
Humans , Vitamins/therapeutic use , Drug Utilization , Vitamins/adverse effects
16.
Washington, D. C; OPS/OMS; CESNI; Fundación CAVENDES; 1997. 473-82 p. (INCAP/PCE/049).
Monography in Spanish | LILACS | ID: lil-224280
17.
Arch. venez. farmacol. ter ; 16(1): 25-36, 1997. tab
Article in Spanish | LILACS | ID: lil-225776

ABSTRACT

Vitamin needs have historically been estimated from the amount of milk consumed by breastfed infants. This approach may be limited by the fact that the milk consumption of breastfed infants is lower than formula-fed infants and the biovallability of the various vitamins may be different human milk compared to formula. For now, using the recommendations of AAPCON as well as clinical observation and experience will determine the appropriate vitamin needs of the population. The maternal diet strogly influences the concentration of certain watersoluble vitamins in human milk. Multivitamin supplements should be given to breast fed infants of malnourished mothers. Overt clinical deficiency of the ninne water-soluble vitamins is not observed in full-term, breast-fed infants of adequately nourished mothers or in commercial formula-fed infants. Vitamins and minerals are incorporate into processed formulas to help provide an essentially complete diet for infants. Most commercial infant formulas contain adequate quantities of vitamins to meet the recommended dally allowances if the infant consumes 750 ml of formula. According to standards recommended by the AAPCON, infants consuming adequate amounts of commercial iron-containing formulas do not need vitamin and mineral supplementation in the first 6 months of life if formula continues to be used with appropriately fortified solid foods. The exact vitamin needs of the preterm infant are unknown. These needs are proportionately greater than term infants due to low stores at birth, sometimes delayed nutritional intervention, increased demands of more rapid growth rate and less complete intestinal digestion and absorption. When fed human milk, the preterm may not receive adequate amounts of some vitamins. Thus human milk supplemented with water-soluble vitamins should be given to preterm infants. It has been recommended by AAPCON to continue this vitamin supplement until the infant's intake exceeds 300 kcal/day or until the infant's acheives a body weight of 2.5 kg


Subject(s)
Humans , Male , Female , Infant, Newborn , Antioxidants/administration & dosage , Antioxidants/adverse effects , Antioxidants/therapeutic use , Infant, Newborn , Neonatology , Vitamins/administration & dosage , Vitamins/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL